Supplemental information

Supplemental Tables

Supplemental Table 1. Characteristics of GIST patients for the immunohistochemistry study

	LOCALIZED DISEASE Number (Frequency%)	METASTATIC DISEASE Number (Frequency%)
Patients	N=67	N=24
Gender (male/female)	36/31 (54/46)	16/8 (67/33)
Age at diagnosis (mean± SD)	57±28	56±28
Primary tumor site		
Stomach	35(52)	4 (17)
Small intestine	14(21)	13 (54)
Others	18(27)	7 (29)
Miettinen Classification		NA
High risk	34(51)	
Intermediate risk	9 (14)	
Low risk	19(28)	
ND*	5 (7)	
Site of Metastasis	NA**	
Liver		5 (21)
Peritoneum		12 (50)
Both		5 (21)
ND*		2 (8)
KIT mutation		
Exon 11	42(63)	10 (42)
Exon 9	4 (6)	2 (8)
Wild-type	13 (19)	5 (21)
ND*	8 (12)	7 (29)
Imatinib targeted therapy		
Untreated	38 (57)	3 (11)
Neo-adjuvant	10 (15)	14 (58)
Adjuvant	19 (28)	7 (29)
Events		
No event	43(64)	0 (0)
Local relapse	2(3)	2 (8)
Metastatic relapse	10(15)	17 (71)
Local+Metastatic relapse	12(18)	5 (21)
Clinical outcome ***		
NED	45(67)	2 (8)
AWD	7(10)	9 (38)
Dead of Disease	9(14)	11 (46)
Dead unrelated to disease	6 (9)	2 (8)
Follow up (years± SD)	4.95 ±16	4.1±12

* ND: Not Determined; ** NA: Not Applicable; ***NED: Non Evolutive Disease, AWD: Alive with Disease

Supplemental Table 2. Characteristics of GIST and STS patients studied in flow cytometry.

	Number (Frequency%)
GIST Patients	N=14
Gender (male/female)	6/8 (43/57)
Age at diagnosis(mean± SD)	59±17
Primarytumor site	
Stomach	5(36)
Small intestine	5(36)
Others	4(28)
Metastasis	2(14)
Site of Metastasis	
Liver	2
Miettinen Classification	
High risk	6(43)
Intermediaterisk	1(7)
Lowrisk	7(50)
KIT mutation	
Exon 11	6(43)
Exon 9	1(7)
Wild-type	0(0)
ND*	7(50)
Imatinib targeted therapy	
Untreated	6(43)
Neo-adjuvant	5(36)
Adjuvant	3(21)
Events	
No event	12(86)
Local relapse	1(7)
Metastatic relapse	0(0)
Clinical outcome	
Non evolutive disease	11(78)
Alive with disease	3(22)
Follow up (months ; means± SD)	15 ± 27
	Numbers (N=)
Soft Tissue Sarcoma Patients	N=6
Gender (male/female)	5/1(83/17)
Age at diagnosis (mean± SD)	48±19
Type of Sarcoma	
Rhabdomyosarcoma	2(33)
Neurosarcoma	2(33)
Liposarcoma	1(17)
Spindle cell sarcoma	1(17)
Treatment	
Untreated	2(33)
Radiotherapy	2(33)
Adriamycine+Ifosfamide	2(33)

* ND: Not Determined

Supplemental Table 3: Antibodies for flow cytometry and IHC.

Ab	Clone	Conjugated	Company
CD3	BW264/56	VioBlue	Miltenyi
CD45	J33	APC-750	Beckman Coulter
CD56	N901	PC7	Beckman Coulter
CD4	SK3	PerCP	BD
CD8	RPA-T8	Fitc	BD
CD16	3G8	Fitc	Beckman Coulter
CD94	HP-3D9	APC	BD
NKp30	AF29-4D12	PE	Miltenyi
NKp44	2.29	APC	Miltenyi
NKp46	9 E2	APC	Miltenyi
NKG2D	BAT221	APC	Miltenyi
NKG2A	131411	APC	R&D
NKG2C	134591	PerCP	R&D
NKp80	239127	APC	R&D
DNAM-1	102511	Pe	R&D
CD158a, h	11PB6	FITC	Miltenyi
CD158b	DX27	PerCP	Miltenyi
CD158e, k	5.133	PE	Miltenyi
CD158i	JJC11.6	APC	Miltenyi
CD69	FN50	FITC	BD
CX3CR1	2A9-1	FITC	BD
CXCR3	49801	PerCP	R&D
CXCR1	8F1	FITC	Biolegend
CD25	M-A251	PE	BD
CD127	eBioRDR5	AF647	eBioscience
CD34	581	FITC	Beckman Coulter
CD117 (KIT)	M-A251	PE	BD
HLA-ABC	G46-2.6	APC	BD
HLA-DR	Immu-357	Pacific Blue	Beckman Coulter
HLA-E	3D12	PE	Biolegend
B7H1 (PDL-1)	29 E.2A4	APC	Biolegend
B7H3	DCN70	PE	Biolegend
B7H6	17B1.3	AF647	E.Vivier
MICA/B	6D4	APC	Biolegend
IFN γ	25723.11	FITC	BD
TNF α	6401.1111	APC	R&D
NKp46	195314	5µg/mL	R&D
CD3	A452	1µg/mL	DakoCytomation
CD8	SP16	1/100	Springbioscience
FoxP3	mAbcam450	4µg/mL	Abcam
Pan HLA class I	EMR8-5	15µg/mL	Cliniscience

Supplemental Figure legend

Supplemental Figure 1. Correlation between T and NK cell infiltrates and the 3-digit Miettinen score.

The enumeration of NKp46, CD3 and Foxp3 cells (left, middle and right panel respectively, (as defined in Figure 1) was correlated with the mitotic index in 50 fields at a x400 power of magnification (A), with the tumor location (B, S: Stomach, SI: Small Intestine, or other) and with the tumor size in cm (C). The number of specimens is indicated on the figure. The median numbers/field are represented, each dot featuring one GIST. Mann Whitney test : *p<0.05, **p<0.01, ***p<0.001.

Supplemental Figure 2. GIST TIls are mainly composed of $CD4^+$ T cells.

Flow cytometric analyses of the percentages of $CD8^+$, $CD4^+$ T cells and $CD4^+CD25^{high}CD127^{low}$ T cells in primary GIST and STS are indicated for paired blood and tumor specimen.

Supplemental Figures



Supplemental Figure 1



Supplemental Figure 2